Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Toward a cure for chronic myeloid leukemia.

Literature DB >> 19088011

Toward a cure for chronic myeloid leukemia.

Thomas O'Hare¹, Michael W Deininger.

Abstract

Entities: CellLine Chemical Disease Gene Mutation Species

Mesh：

Substances：

Year: 2008 PMID： 19088011 PMCID： PMC2614298 DOI： 10.1158/1078-0432.CCR-08-1486

Source DB: PubMed Journal: Clin Cancer Res ISSN： 1078-0432 Impact factor: 12.531

× No keyword cloud information.

27 in total

1. Bedside to bench: interfering with leukemic stem cells.

Authors: Daniela S Krause; Richard A Van Etten
Journal: Nat Med Date: 2008-05 Impact factor: 53.440

Review 2. Getting to the stem of chronic myeloid leukaemia.

Authors: Michael Savona; Moshe Talpaz
Journal: Nat Rev Cancer Date: 2008-05 Impact factor: 60.716

3. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase.

Authors: T Schindler; W Bornmann; P Pellicena; W T Miller; B Clarkson; J Kuriyan
Journal: Science Date: 2000-09-15 Impact factor: 47.728

4. Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl protein stability in imatinib-resistant chronic myelogenous leukemia cells.

Authors: Ji Wu; Feng Meng; Henry Lu; Ling Kong; William Bornmann; Zhenghong Peng; Moshe Talpaz; Nicholas J Donato
Journal: Blood Date: 2008-01-30 Impact factor: 22.113

5. Solution conformations and dynamics of ABL kinase-inhibitor complexes determined by NMR substantiate the different binding modes of imatinib/nilotinib and dasatinib.

Authors: Navratna Vajpai; André Strauss; Gabriele Fendrich; Sandra W Cowan-Jacob; Paul W Manley; Stephan Grzesiek; Wolfgang Jahnke
Journal: J Biol Chem Date: 2008-04-22 Impact factor: 5.157

6. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants.

Authors: Thomas O'Hare; Denise K Walters; Eric P Stoffregen; Taiping Jia; Paul W Manley; Jürgen Mestan; Sandra W Cowan-Jacob; Francis Y Lee; Michael C Heinrich; Michael W N Deininger; Brian J Druker
Journal: Cancer Res Date: 2005-06-01 Impact factor: 12.701

7. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia.

Authors: Philipp le Coutre; Oliver G Ottmann; Francis Giles; Dong-Wook Kim; Jorge Cortes; Norbert Gattermann; Jane F Apperley; Richard A Larson; Elisabetta Abruzzese; Stephen G O'Brien; Kazimierz Kuliczkowski; Andreas Hochhaus; Francois-Xavier Mahon; Giuseppe Saglio; Marco Gobbi; Yok-Lam Kwong; Michele Baccarani; Timothy Hughes; Giovanni Martinelli; Jerald P Radich; Ming Zheng; Yaping Shou; Hagop Kantarjian
Journal: Blood Date: 2007-11-29 Impact factor: 22.113

8. SGX393 inhibits the CML mutant Bcr-AblT315I and preempts in vitro resistance when combined with nilotinib or dasatinib.

Authors: Thomas O'Hare; Christopher A Eide; Jeffrey W Tyner; Amie S Corbin; Matthew J Wong; Sean Buchanan; Kevin Holme; Katayoun A Jessen; Crystal Tang; Hal A Lewis; Richard D Romero; Stephen K Burley; Michael W Deininger
Journal: Proc Natl Acad Sci U S A Date: 2008-03-26 Impact factor: 11.205

9. Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia.

Authors: Thomas O'Hare; Christopher A Eide; Michael W N Deininger
Journal: Blood Date: 2007-05-11 Impact factor: 22.113

10. Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency.

Authors: Neil P Shah; Brian J Skaggs; Susan Branford; Timothy P Hughes; John M Nicoll; Ronald L Paquette; Charles L Sawyers
Journal: J Clin Invest Date: 2007-09 Impact factor: 14.808

3 in total